Letter to the Editor
Are metastatic central lymph nodes (D3 volume) in right-sided colon cancer “REALLY” a sign of systemic disease?—a sub-group analysis of an ongoing multicenter trial
AME Clinical Trials Review
2024;
2:
91
(25 October 2024)
Editorial Commentary
One more point for ibrutinib plus rituximab over fludarabine, cyclophosphamide and rituximab (FCR)
AME Clinical Trials Review
2024;
2:
90
(25 October 2024)
Editorial Commentary
The optimum balance between efficacy and toxicity with different doses of trastuzumab deruxtecan in HER2 mutated non-small cell lung cancer in DESTINY-Lung02 trial
AME Clinical Trials Review
2024;
2:
89
(25 October 2024)
Editorial Commentary
Advancing hepatocellular carcinoma treatment: a triple combination for patients with extrahepatic metastasis—better or bust?
AME Clinical Trials Review
2024;
2:
88
(25 October 2024)
Editorial Commentary
Teamwork makes the dream work?—dissecting the role of triple therapy: radiotherapy combined with sintilimab plus bevacizumab for hepatocellular carcinoma and malignant portal vein invasion
AME Clinical Trials Review
2024;
2:
87
(25 October 2024)
Editorial Commentary
A new ALK inhibitor is not a game changer, but an older one is!
AME Clinical Trials Review
2024;
2:
86
(25 October 2024)
Editorial Commentary
Utilizing therapeutic response as a criterion for PARP inhibitor maintenance therapy in advanced triple negative breast cancer; promoting personalized medicine
AME Clinical Trials Review
2024;
2:
85
(25 October 2024)
Editorial Commentary
Open surgery may no longer be a control arm of minimally invasive surgery for gastric cancer
AME Clinical Trials Review
2024;
2:
84
(25 October 2024)
Editorial Commentary
Tislelizumab: a promising alternative first-line systemic therapy in unresectable advanced hepatocellular carcinoma
AME Clinical Trials Review
2024;
2:
83
(25 October 2024)
Editorial Commentary
Adding pieces to immunotherapy puzzle in biliary tract cancer
AME Clinical Trials Review
2024;
2:
82
(25 October 2024)
Editorial Commentary
Panning for gold in a dry creek?—the ongoing search for role of immunotherapy in mismatch repair proficient rectal cancer
AME Clinical Trials Review
2024;
2:
81
(25 October 2024)
Editorial Commentary
Peposertib as a radiosensitizing agent in the treatment of locally advanced rectal cancer
AME Clinical Trials Review
2024;
2:
80
(25 October 2024)
Editorial Commentary
Mechanical and oral antibiotic bowel prep should be standard before elective rectal resection
AME Clinical Trials Review
2024;
2:
79
(25 October 2024)
Editorial Commentary
TARMAC trial—a new path for chimeric antigen receptor (CAR) T in relapsed mantle cell lymphoma (MCL)?
AME Clinical Trials Review
2024;
2:
78
(25 October 2024)
Editorial Commentary
Synergising hypomethylating agents with immunotherapy in renal cell carcinoma: unlocking the potential of an old classic
AME Clinical Trials Review
2024;
2:
77
(25 October 2024)
Editorial Commentary
Targeting the TGF-β pathway in patients with non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
76
(25 October 2024)
Editorial Commentary
The ‘right’ timing for durvalumab after chemoradiation in stage III non-small cell lung cancer
AME Clinical Trials Review
2024;
2:
75
(25 October 2024)
Editorial Commentary
Beyond the PARP inhibition: what is the future of ovarian cancer treatment?
AME Clinical Trials Review
2024;
2:
74
(25 October 2024)
Editorial Commentary
What is the role of perioperative immunotherapy and chemotherapy in stage III resectable non-small cell lung cancer?
AME Clinical Trials Review
2024;
2:
73
(25 October 2024)
Editorial Commentary
Progress in the integration of radiation therapy and checkpoint inhibition in hepatocellular carcinoma
AME Clinical Trials Review
2024;
2:
72
(25 October 2024)
Editorial Commentary
Is ribociclib plus endocrine therapy effective for high-risk early breast cancer?
AME Clinical Trials Review
2024;
2:
71
(25 October 2024)
Editorial Commentary
Lisocabtagene maraleucel: transcending tolerability in CAR-T for mantle cell lymphoma
AME Clinical Trials Review
2024;
2:
70
(25 October 2024)
Editorial Commentary
Romidepsin in peripheral T-cell lymphomas: current updates and treatment considerations
AME Clinical Trials Review
2024;
2:
69
(25 October 2024)
Editorial Commentary
The TRACE-II trial: will this draw the path for radioguided surgery and androgen deprivation therapy combination, or not?
AME Clinical Trials Review
2024;
2:
68
(25 October 2024)
Editorial Commentary
Five-year update of the gastric cancer adjuvant therapy JCOG1104 trial: how much therapy is enough?
AME Clinical Trials Review
2024;
2:
67
(25 October 2024)
Editorial Commentary
Current evidence for neoadjuvant therapy in resectable pancreatic cancer
AME Clinical Trials Review
2024;
2:
66
(25 October 2024)
Editorial Commentary
Is three always greater than two?—azacitidine, venetoclax, and gilteritinib triple therapy in newly diagnosed and relapsed/refractory FLT3-mutant acute myeloid leukemia
AME Clinical Trials Review
2024;
2:
65
(25 October 2024)
Editorial Commentary
SUBDUE-1: sub-urothelial immunotherapy to balance effectiveness and safety in Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer?
AME Clinical Trials Review
2024;
2:
64
(25 October 2024)
Editorial Commentary
Ticagrelor or clopidogrel for patients with chronic coronary syndrome undergoing complex percutaneous coronary intervention?—the verdict has not been delivered yet
AME Clinical Trials Review
2024;
2:
63
(25 October 2024)
Editorial Commentary
Adjuvant immunotherapy in hepatocellular carcinoma: effective for Asian only, or for all patients?
AME Clinical Trials Review
2024;
2:
62
(25 August 2024)